Showing 121 - 140 results of 100,440 for search '(( 5 non decrease ) OR ( 5 ((((nn decrease) OR (a decrease))) OR (we decrease)) ))', query time: 1.65s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124
  5. 125
  6. 126
  7. 127
  8. 128
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134

    Table_1_Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.docx by Ha Young Jang (1522204)

    Published 2022
    “…The cancer risk showed a tendency to decrease rapidly when LTRAs were used in high dose (aHR = 0.56, 95% CI = 0.40–0.79) or for longer durations of more than 3 years (aHR = 0.68, 95% CI = 0.60–0.76) and 5 years (aHR = 0.33, 95% CI = 0.26–0.42). …”
  15. 135
  16. 136
  17. 137
  18. 138

    Data_Sheet_1_Improved body composition decreases the fat content in non-alcoholic fatty liver disease, a meta-analysis and systematic review of longitudinal studies.docx by Dóra Mátis (15407060)

    Published 2023
    “…Background<p>Based on cross-sectional studies, there is a link between body composition parameters and steatosis in non-alcoholic fatty liver disease (NAFLD). …”
  19. 139

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  20. 140